

Johnson and Johnson Company Profile



At a Glance

Johnson and Johnson (J&J; "The Company") is an American health and well-being company founded and incorporated in New Brunswick, New Jersey.

Johnson and Johnson and its subsidiaries have approximately 134,500 employees operating out of virtually every country in the world with the primary focus on products related to life sciences. Johnson and Johnson is organized into three business segments:

- **The Consumer Health** division includes a range of products used in over-the-counter pharmaceutical, women's health, infant health, oral health, dermatological care, and wound care markets sold through eCommerce and retail outlets throughout the world.
- The **Pharmaceutical** segment focuses on 6 therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases.
- **Medical Devices** include a broad range of products used in the orthopedic surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields. This segment is used mainly in professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

Key Figures

Total Assets

\$182*

2021 Asset total is a .4% increase from 2020

R&D Expenses

\$12.2*

R&D increased 5.7% from 2020 to 2021.

Market Capital

\$450.3*

2021 Market Capital is a 8.7% Increase from 2020

Annual Litigation Expenses

\$5.1*

Consumer Health Segment increased spending from \$4b in 2019 to \$3.9b in 2020.

Total Patents

3,342

32.4% require attention by 2024

Revenue

\$94.88*

Revenue increased 5.1% from 2020 to 2021

**In Billions*

Mission

- The Company is committed to bringing its full breadth and depth to ensure health for people today and for future generations.
- The Company's Purpose is to blend heart, science and ingenuity to profoundly change the trajectory of health for humanity.
- The Company is broadly based in human healthcare, and is committed to creating value by developing accessible, high quality, and innovative products and services.

Highlights

- **Corona Virus** The FDA sharply limits use of Johnson and Johnson shot due to rare blood clots. Other vaccines said to be safer.
- **Curing Cancer** Subsidiary Janssen Presents Encouraging Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma.
- **Company Split** Johnson and Johnson announced in November 2021 plans to separate the Company's Consumer Health business, which will create a new publicly traded company. The consumer health company would house brands such as Neutrogena, AVEENO, Tylenol, Listerine, JOHNSON's, and BAND-AID. This change will take effect by November 2023.

Litigation of Interest

- Johnson and Johnson is required to pay up to \$5 billion in the next nine years as part of a collective \$26 billion paid by three key players in the United States' opioid epidemic. As part of the settlement, Johnson and Johnson has made a ten year commitment to stop selling opioids, stop providing grants to third parties for promoting opioids, and will share clinical trial data under the Yale University Open Data Access Project.
- North Carolina Attorney General Josh Stein settles with Johnson and Johnson for \$116.9 Million. This is a multistate settlement with J&J and its subsidiary Ethicon Inc. regarding "deceptive" marketing of certain medical devices.
- The Company won a key court case that allowed a subsidiary to file for bankruptcy, avoiding impending talcum powder class action suits, but an appellate court said in May that they will see the case. The company is accused of lying about the presence of asbestos in its market dominating baby powder. In April leadership voted not to pull its baby powder from the global market.

Notable Acquisitions

- Abbott Medical Optics, \$4.33 Billion, May 2017; Known for diagnostics, medical devices, nutrition products, and branded generic pharmaceuticals.
- Synthes, \$19.7 Billion, 2018; Specialties include joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine.
- Auris Health, \$3.45 Billion, Aug 2019; Robotic medical company.
- Crucell, \$2.3 Billion, Sep 2019; Biotechnology company specializing in vaccines and biopharmaceutical technologies.
- OrthoSpin, \$29.5 Million, Nov 2021; Orthopedic Device Manufacturer.
- Micrus Endovascular, \$480 Million, Jan 2022; San Jose, Calif.-based maker of cerebral vascular devices .
- Crossroads Extremity Systems, Undisclosed, Orthopedic Device Manufacturer.

2021 Health for Humanity Report

This report shares progress against The Company's purpose-driven Health for Humanity 2025 Goals and serves as its annual disclosure on environmental, social, and governance (ESG) performance.

Four Priorities:

- **Global Health Equity:** *"Our commitment to advancing global health equity incorporates our active efforts and collaborations to enhance access to medical treatment and healthcare for all people while breaking down historic racial and social barriers that hinder access to equitable healthcare solutions."*
- **Employees:** Focuses on efforts of "DEI," diversity, equity, and inclusion.
- **Environmental Health:** J&J is committed to mitigate its' impact on climate change.
- **Accountability and Innovation:** By engaging at the supplier level, Johnson and Johnson seeks to increase diversity and sustainability.

Firm Contacts

- John Doe, New York, NY. Associate General Counsel at J&J (2015-present)
Former Troutman Pepper partner (2005-2015)
- Jane Doe, New Brunswick, NJ Chief of Staff at J&J (2020-present)
Former Merck and Troutman Pepper client

Notable Representation

- ABC Firm representing J&J on Bankruptcy Litigation (Source: Westlaw)
- DEF Firm representing J&J on Talcum Powder Litigation (Source: LexisNexis)
- XYZ Firm representing J&J on acquisition of MNO Pharmaceuticals (SEC 8-K)

Sources

- "Johnson & Johnson Reports Q4 and Full-Year 2021 Results." Jan 25, 2022. <https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/johnson-johnson-reports-q4-and-full-year-2021-results>
- "Attorney General Josh Stein Settles with Johnson & Johnson for \$116.9 Million". Oct 17, 2019. <https://ncdoj.gov/attorney-general-josh-stein-settles-with-johnson-johnson-for-116-9-million/>
- "Attorney General Josh Stein Announces \$26 Billion Agreement with Opioid Distributors/Manufacturer." Jul 21, 2021. <https://ncdoj.gov/attorney-general-josh-stein-announces-26-billion-agreement-with-opioid-distributors-manufacturer/>
- "Form 10-Q." (Consolidated financial statements). Apr 3, 2022. <https://sec.report/Document/0000200406-22-000048/>
- "Johnson and Johnson: Corporate Rap Sheet." Nov 14, 2021. <https://www.corp-research.org/jnj>
- "2021 Johnson and Johnson Annual Report." Mar 01, 2022. <https://www.investor.jnj.com/annual-meeting-materials/2021-annual-report>
- "Johnson and Johnson SEC Filing." April 30, 2021. <https://sec.report/CIK/0000200406>
- "2021 Health for Humanity Report." November 1, 2021. <https://healthforhumanityreport.jnj.com/johnson-johnson-2021-health-for-humanity-report-pdf>
- "What does a more aggressive M&A approach mean for J&J's devices unit?." Feb 22, 2022. <https://www.medtechdive.com/news/JnJ-mergers-acquisitions-medical-devices/619073/>